Tickers

1. Composite Trajectory Verdict

The income statement carries the most weight for assessing KLAC's trajectory given its high-margin, asset-light semiconductor equipment model where revenue growth, margin expansion, and earnings conversion drive value creation.

Composite Trajectory: Improving

Annual results show consistent improvement across three fiscal years: revenue grew 24% (FY2025 vs FY2024) and 12% (FY2026 vs FY2025) to $13.58B; gross margin expanded from 60.0% to 60.9% to 61.3%; net income rose 47% then 19% to $4.83B; diluted EPS increased from $2.03 to $3.04 to $3.66 (10-K FY2026, Consolidated Statements of Operations). Operating cash flow grew each year to $4.14B, funding $2.29B in buybacks and $1.06B in dividends in FY2026 (10-K FY2026, Consolidated Statements of Cash Flows). The balance sheet strengthened with cash and marketable securities rising to $4.90B, stockholders' equity increasing to $6.35B, and working capital expanding to $8.08B (10-K FY2026, Consolidated Balance Sheets). Quarterly data shows continued revenue growth (Q3 FY2026 +11.5% YoY to $3.42B) but gross margin compressed 50bps YoY to 61.1% and accounts receivable grew 27.6% annually vs 12% revenue growth, creating a mixed near-term signal that does not offset the clear multi-year improvement.

2. Red Flags

• Gross margin declined sequentially for three consecutive quarters: 62.0% (Q4 FY2025) → 61.3% (Q1 FY2026) → 61.4% (Q2 FY2026) → 61.1% (Q3 FY2026) despite revenue growth (10-Q 2026-03-31, MD&A Results of Operations)
• Accounts receivable increased 27.6% YoY to $2.89B while revenue grew 12%, and the allowance for credit losses rose 28% to $31.0M with provision for credit losses jumping $23.1M in Q3 FY2026 and $26.1M in 9M FY2026 (10-K FY2026, Note 4; 10-Q 2026-03-31, MD&A SG&A)
• Inventories grew 13.6% YoY to $3.65B, outpacing 12% revenue growth (10-K FY2026, Consolidated Balance Sheets)
• Goodwill and intangible asset impairments recorded in two consecutive years: $289.5M in FY2024 and $239.1M in FY2025, both in PCB and Component Inspection segment (10-K FY2026, Note 6)
• China revenue flat at ~$4.05B for three years while total revenue grew 38%, reducing China share from 42.8% to 29.8% (10-K FY2026, MD&A Revenues by region)
• Purchase commitments of $5.97B as of June 30, 2026, majority due within 12 months (10-K FY2026, Note 15)

3. Earnings Assessment (Income Statement)

Earnings Trajectory: Improving

Annual GAAP results show three years of consistent improvement: total revenue increased from $9.81B (FY2024) to $12.16B (FY2025) to $13.58B (FY2026) (10-K FY2026, Consolidated Statements of Operations). Gross margin expanded 130bps over the period to 61.3% (10-K FY2026, MD&A Gross Margin). Net income grew from $2.76B to $4.06B to $4.83B, with diluted EPS rising from $2.03 to $3.04 to $3.66 (10-K FY2026, Consolidated Statements of Operations). R&D expense as a percentage of revenue improved from 13% to 11% and held at 11%; SG&A improved from 10% to 8% and held at 8% (10-K FY2026, MD&A R&D and SG&A). Segment profit for Semiconductor Process Control grew from $3.77B to $5.00B to $5.48B; PCB and Component Inspection swung from a $(470M) loss to $(281M) to $108M profit (10-K FY2026, Note 17). Quarterly Q3 FY2026 showed revenue +11.5% YoY but gross margin -50bps YoY to 61.1% and SG&A as % of revenue up to 9% from 8% (10-Q 2026-03-31, MD&A Results of Operations).

4. Cash Generation Assessment (Statement of Cash Flows)

Cash Trajectory: Improving

Operating cash flow increased each fiscal year: $3.31B (FY2024) → $4.08B (FY2025) → $4.14B (FY2026) (10-K FY2026, Consolidated Statements of Cash Flows). Free cash flow (CFO minus CapEx) grew from ~$3.03B to ~$3.75B to ~$3.77B as CapEx remained modest at $277M, $335M, and $376M respectively (10-K FY2026, Consolidated Statements of Cash Flows). Nine-month operating cash flow rose 11% to $3.24B (9M FY2026) from $2.92B (9M FY2025) (10-Q 2026-03-31, MD&A Liquidity). Cash returns to shareholders accelerated: dividends paid increased from $773M to $905M to $1.06B; share repurchases from $1.74B to $2.15B to $2.29B (10-K FY2026, Consolidated Statements of Cash Flows). Debt reduced by $750M in FY2025 with no further repayment in FY2026; long-term debt stable at ~$5.89B (10-K FY2026, Consolidated Balance Sheets). Investing cash flow shifted to -$1.19B in FY2026 from -$202M in FY2025 due to $959M increase in net purchases of available-for-sale securities (10-K FY2026, MD&A Liquidity).

5. Balance Sheet Assessment

Balance Sheet Trajectory: Improving

Total assets grew from $16.07B (FY2025) to $17.95B (FY2026) (10-K FY2026, Consolidated Balance Sheets). Cash, cash equivalents, and marketable securities increased from $4.49B to $4.90B (10-K FY2026, Consolidated Balance Sheets). Stockholders' equity surged 35% from $4.69B to $6.35B driven by retained earnings accumulation ($2.18B to $3.68B) (10-K FY2026, Consolidated Statements of Stockholders' Equity). Working capital expanded from $6.61B to $8.08B (10-K FY2026, MD&A Working Capital). Long-term debt remained flat at $5.89B; net leverage ratio 0.53x vs 3.25x covenant (10-K FY2026, MD&A Revolving Credit Facility). Current assets grew 16% to $12.38B; current liabilities grew 5% to $4.30B (10-K FY2026, Consolidated Balance Sheets). Deferred revenue (contract liabilities) increased 4% to $1.78B (10-K FY2026, Note 2). Accumulated other comprehensive income swung from +$1.2M to -$34.5M (10-K FY2026, Consolidated Balance Sheets).

6. Data Gaps

• Quarterly balance sheets for December 31, 2025 and September 30, 2025 not provided in 10-Q filings
• Quarterly cash flow statements for individual quarters (Q1, Q2, Q3 FY2026) not provided; only nine-month aggregates available
• FY2024 balance sheet details not fully presented in 10-K (only FY2025 and FY2026 shown)
• Segment-level operating margins not directly disclosed for all periods; only segment profit before unallocated items
• Breakdown of "Other expense (income), net" components for quarterly periods not fully detailed
• Free cash flow for individual quarterly periods cannot be calculated from provided data
• Inventory turnover and days sales outstanding metrics not computable without quarterly averages